Clinical Research Directory
Browse clinical research sites, groups, and studies.
Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients
Sponsor: Virginia Commonwealth University
Summary
Most kidney transplant recipients take a combination of anti-rejection medicines for the rest of their life. One of these is called mycophenolate mofetil (MMF), also known by the brand name CellCept. While MMF helps protect the kidney, taking it for many years can cause infections, low blood counts, stomach problems, and a higher risk of certain cancers, problems that older adults are especially likely to experience. We are doing this study to learn whether carefully and slowly stopping MMF in older adults who are doing well after their transplant is as safe as continuing MMF, when we use blood and urine tests to closely watch for any early signs of trouble. The information learned could help future kidney transplant patients use less medicine without losing their transplant.
Official title: Optimizing Immunosuppression in Low-Risk Older Adult Kidney Transplant Recipients (OPTIMA-KT): A Prospective, Randomized, Open-Label, Blinded-Endpoint Single-Site Pilot/Feasibility Trial of Biomarker-Guided Mycophenolate Mofetil Elimination
Key Details
Gender
All
Age Range
60 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-08-31
Completion Date
2029-08-01
Last Updated
2026-09-08
Healthy Volunteers
No
Conditions
Interventions
Tacrolimus (Kidney transplant maintenance immunosuppression)
Administration of Tacrolimus
Mycophenoate Mofetil
Participants are administered MMF
Prednisone (SOC arm)
Participants in SOC arm may be administered Prednisone as indicated
Prednisone (MMF Elimination arm)
Participants in the MMF Elimination arm may be administered prednisone as indicated